Disposition of high-dose busulfan in pediatric patients undergoing bone marrow transplantation
Autor: | I. Buggia, Mario Regazzi, Silvana Quaglini, Federico Bonetti, Massimo Pregnolato, Franco Locatelli, Marco Zecca |
---|---|
Rok vydání: | 1993 |
Předmět: |
Hemolytic anemia
Adult Male medicine.medical_specialty Bone marrow transplantation Adolescent medicine.medical_treatment Urology Administration Oral Pharmacokinetics Oral administration medicine Humans Pharmacology (medical) Child Busulfan Bone Marrow Transplantation Pharmacology Chemotherapy Analysis of Variance business.industry Infant medicine.disease Surgery medicine.anatomical_structure Total dose Child Preschool Regression Analysis Female Bone marrow business medicine.drug Half-Life |
Zdroj: | Clinical pharmacology and therapeutics. 54(1) |
ISSN: | 0009-9236 |
Popis: | We studied the pharmacokinetics of busulfan (16 mg/kg) in 16 pediatric patients affected by malignant and nonmalignant disorders between 6 months and 19 years of age (mean ± SD, 5.7 ± 6.5 years) who were undergoing allogeneic (15 patients) and autologous (one patient) bone marrow transplantation. In all children, the conditioning regimen consisted of busulfan given orally at a dose of 1 mg/kg every 6 hours for 16 doses (total dose, 16 mg/kg), associated with other drugs. The pharmacokinetics of busulfan was studied during the 6-hour dosing interval on the third day of therapy by use of a high-performance liquid chromatographie assay. The value for the time to reach maximum concentration, expressed as mean ± SD, was 1.1 ± 0.5 hour; maximum concentration was 609.6 ± 225.3 ng/ml; steady-state concentration was 358.9 ± 135.5 ng/ml; area under the plasma concentration–time curve was 2153.6 ± 813.1 ng · hr/ml; oral clearance was 0.535 ± 0.226 L/hr/kg; and half-life was 2.4 ± 0.8 hours. Age-related differences in busulfan disposition were observed. The mean busulfan oral clearance in a group of 10 patients with an age range from 6 months to 3 years was 0.619 L/hr/kg, whereas six patients whose ages ranged from 7 to 19 years had a oral clearance of 0.396 L/hr/kg. The half-lives for busulfan during infancy decrease continuously until early childhood but were prolonged in older children. No significant relationship between systemic exposure to busulfan and drug effect was observed. Clinical Pharmacology and Therapeutics (1993) 54, 45–52; doi:10.1038/clpt.1993.108 |
Databáze: | OpenAIRE |
Externí odkaz: |